Ignite Creation Date:
2025-12-24 @ 10:36 PM
Ignite Modification Date:
2026-01-01 @ 8:54 PM
Study NCT ID:
NCT05262335
Status:
UNKNOWN
Last Update Posted:
2023-11-28
First Post:
2022-02-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
Sponsor:
Ruijin Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-21
First Submit QC Date:
None
Study First Post Date:
2022-03-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-27
Last Update Post Date:
2023-11-28
Last Update Post Date Type:
ACTUAL